title: [Effect of glatiramer acetate (copaxone) on the structure and functions of the thyroid gland in patients with multiple sclerosis].
abstract: A study included 158 patients stratified into 3 groups: 57 patients with multiple sclerosis (MS) of the main group who were treated with copaxone in dosage 20 mg/d during 4,3±2,6 years, 49 patients without MS with different neurological diseases of the control group and 52 patients diagnosed with "confirmed MS" in the remission stage who were not treated with disease-modifying drugs. Demographic data, severity of MS patient's state, ultra-sound and hormonal data assessing the thyroid gland function were analyzed. The results obtained in the study demonstrated the relative safety of copaxone in respect to changes in thyroid gland function, the low risk for the elevation of blood antibodies to thyreoperoxidase, changes of hormonal indices and the development of thyroid dysfunction.
authors.forename: L V
authors.initials: LV
authors.lastname: Petrova
authors.forename: A N
authors.initials: AN
authors.lastname: Boĭko
authors.forename: T T
authors.initials: TT
authors.lastname: Batysheva
authors.forename: E I
authors.initials: EI
authors.lastname: Gusev
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D010455:Peptides / Q000009:adverse effects* / Q000627:therapeutic use; D013961:Thyroid Gland / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents; D010455:Peptides; D000068717:Glatiramer Acetate